{"id":"https://openalex.org/W2217233644","doi":"https://doi.org/10.1385/1-59259-854-4:085","title":"Clinical Studies of Antisense Oligonucleotides for Cancer Therapy","display_name":"Clinical Studies of Antisense Oligonucleotides for Cancer Therapy","publication_year":2004,"publication_date":"2004-09-16","ids":{"openalex":"https://openalex.org/W2217233644","doi":"https://doi.org/10.1385/1-59259-854-4:085","mag":"2217233644","pmid":"https://pubmed.ncbi.nlm.nih.gov/15375314"},"language":"en","primary_location":{"id":"doi:10.1385/1-59259-854-4:085","doi":"https://doi.org/10.1385/1-59259-854-4:085","is_oa":false,"landing_page_url":"https://doi.org/10.1385/1-59259-854-4:085","pdf_url":null,"source":{"id":"https://openalex.org/S4306463399","display_name":"Humana Press eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310315801","host_organization_name":"Humana Press","host_organization_lineage":["https://openalex.org/P4310315801","https://openalex.org/P4310319900"],"host_organization_lineage_names":["Humana Press","Springer Science+Business Media"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antisense Therapeutics","raw_type":"book-chapter"},"volume":{"id":"https://openalex.org/W4234993368","display_name":"Antisense Therapeutics"},"type":"book-chapter","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113552095","display_name":"Rosanne M. Orr","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rosanne M. Orr","raw_affiliation_strings":["Cancer Research UK Centre for Cancer Therapeutic, The Institute of Cancer Research, Sutton, Surrey, UK","Cancer Research UK Centre for Cancer Therapeutic, The Institute of Cancer Research, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research UK Centre for Cancer Therapeutic, The Institute of Cancer Research, Sutton, Surrey, UK","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]},{"raw_affiliation_string":"Cancer Research UK Centre for Cancer Therapeutic, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031039438","display_name":"F. Andrew Dorr","orcid":"https://orcid.org/0009-0004-7367-1419","observed_orcids":["https://orcid.org/0009-0004-7367-1419"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Andrew Dorr","raw_affiliation_strings":["Salmedix Inc., San Diego","Salmedix Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Salmedix Inc., San Diego","institution_ids":[]},{"raw_affiliation_string":"Salmedix Inc","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.7918,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.85525071,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"106","issue":null,"first_page":"085","last_page":"112"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.37549999356269836,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.37549999356269836,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10432","display_name":"DNA and Nucleic Acid Chemistry","score":0.3596000075340271,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.04179999977350235,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antisense-oligonucleotides","display_name":"antisense oligonucleotides","score":1.0},{"id":"https://openalex.org/keywords/cancer-therapy","display_name":"cancer therapy","score":0.9789999723434448},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6330000162124634},{"id":"https://openalex.org/keywords/conventional-chemotherapy","display_name":"cytotoxic chemotherapy","score":0.5960000157356262},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8790000081062317},{"id":"https://openalex.org/keywords/small-molecule-kinase-inhibitors","display_name":"small-molecule kinase inhibitors","score":0.6629999876022339},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.8379999995231628},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.8320000171661377},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/targeted-cancer-therapy","display_name":"targeted cancer therapy","score":0.546999990940094},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.48899999260902405},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.4519999921321869},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.6859999895095825}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6560759544372559},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5983734130859375},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.5673657655715942},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5625372529029846},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.489957720041275},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.4765903651714325},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.4601064920425415},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4462594985961914},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.4355137050151825},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2597898840904236},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2316928207874298},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.20538413524627686},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D011493","descriptor_name":"Protein Kinase C","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D011905","descriptor_name":"Genes, ras","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012264","descriptor_name":"Ribonucleotide Reductases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015254","descriptor_name":"DNA Modification Methylases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016158","descriptor_name":"Genes, p53","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016376","descriptor_name":"Oligonucleotides, Antisense","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017868","descriptor_name":"Cyclic AMP-Dependent Protein Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019253","descriptor_name":"Proto-Oncogene Proteins c-bcl-2","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019908","descriptor_name":"Proto-Oncogene Proteins c-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D020598","descriptor_name":"Proto-Oncogene Proteins c-myb","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D051571","descriptor_name":"Protein Kinase C-alpha","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1385/1-59259-854-4:085","doi":"https://doi.org/10.1385/1-59259-854-4:085","is_oa":false,"landing_page_url":"https://doi.org/10.1385/1-59259-854-4:085","pdf_url":null,"source":{"id":"https://openalex.org/S4306463399","display_name":"Humana Press eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310315801","host_organization_name":"Humana Press","host_organization_lineage":["https://openalex.org/P4310315801","https://openalex.org/P4310319900"],"host_organization_lineage_names":["Humana Press","Springer Science+Business Media"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antisense Therapeutics","raw_type":"book-chapter"},{"id":"pmid:15375314","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15375314","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Methods in molecular medicine","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":65,"referenced_works":["https://openalex.org/W20453933","https://openalex.org/W81907876","https://openalex.org/W108005309","https://openalex.org/W1493046933","https://openalex.org/W1528035347","https://openalex.org/W1533077869","https://openalex.org/W1575330800","https://openalex.org/W1585017744","https://openalex.org/W1588936614","https://openalex.org/W1821878109","https://openalex.org/W1856630099","https://openalex.org/W1963042350","https://openalex.org/W1964053904","https://openalex.org/W1966035396","https://openalex.org/W1970066197","https://openalex.org/W1971162298","https://openalex.org/W1982410689","https://openalex.org/W1995142741","https://openalex.org/W1998297552","https://openalex.org/W2000025384","https://openalex.org/W2008179206","https://openalex.org/W2019687915","https://openalex.org/W2025295254","https://openalex.org/W2026050954","https://openalex.org/W2030889696","https://openalex.org/W2037758170","https://openalex.org/W2042815563","https://openalex.org/W2045418379","https://openalex.org/W2049938167","https://openalex.org/W2056745327","https://openalex.org/W2057257609","https://openalex.org/W2079804110","https://openalex.org/W2093965961","https://openalex.org/W2097092276","https://openalex.org/W2099515475","https://openalex.org/W2113425358","https://openalex.org/W2123087552","https://openalex.org/W2128559106","https://openalex.org/W2130541596","https://openalex.org/W2134404472","https://openalex.org/W2144473160","https://openalex.org/W2145888569","https://openalex.org/W2147478255","https://openalex.org/W2147730379","https://openalex.org/W2151190428","https://openalex.org/W2159594827","https://openalex.org/W2167368130","https://openalex.org/W2167742104","https://openalex.org/W2245205914","https://openalex.org/W2248643920","https://openalex.org/W2282576168","https://openalex.org/W2290539832","https://openalex.org/W2312804644","https://openalex.org/W2318605753","https://openalex.org/W2318612270","https://openalex.org/W2323964932","https://openalex.org/W2331400535","https://openalex.org/W2394799824","https://openalex.org/W2403381121","https://openalex.org/W2410579556","https://openalex.org/W2415007543","https://openalex.org/W2415543020","https://openalex.org/W2416193697","https://openalex.org/W2418623730","https://openalex.org/W2492195922"],"related_works":["https://openalex.org/W2112517078","https://openalex.org/W1999273508","https://openalex.org/W1990507217","https://openalex.org/W4251903173","https://openalex.org/W2154519280","https://openalex.org/W1986714349","https://openalex.org/W1999033641","https://openalex.org/W2093602335","https://openalex.org/W4242873024","https://openalex.org/W123358795"],"abstract_inverted_index":{"Until":[0],"now,":[1],"the":[2,13,31,44,79,103,119,145,150,155,196],"clinical":[3,186],"demise":[4],"of":[5,15,36,46,82,121,133,144,159,179,198,208],"cancer":[6,88,128,201],"has":[7,39,73,110,153,183],"relied":[8],"on":[9,113],"surgical":[10],"resection":[11],"and":[12,51,66,90,130,157,182,217],"inhibition":[14],"tumor":[16,55],"cell":[17],"proliferation":[18],"using":[19],"ionizing":[20],"radiation":[21],"or":[22,30,98,106,142],"chemotherapeutic":[23],"drugs":[24,59,194],"designed":[25],"to":[26,84,125,140],"perturb":[27],"DNA":[28],"synthesis":[29],"mitotic":[32],"event.":[33],"The":[34],"development":[35,120,156],"cytotoxic":[37,76],"agents":[38],"resulted":[40],"in":[41,43,176,190],"improvements":[42],"treatment":[45,197],"leukemia,":[47],"lymphoma,":[48],"testicular":[49],"cancer,":[50],"many":[52],"other":[53,193],"solid":[54],"types":[56],"().":[57,69],"Hormone-based":[58],"have":[60,137],"also":[61],"been":[62,74,111,138],"useful":[63],"for":[64,195],"breast":[65,180,200],"prostate":[67],"cancers":[68,181],"Although":[70],"much":[71],"success":[72],"achieved,":[75],"modalities":[77],"walk":[78],"therapeutic":[80,115],"tightrope":[81],"toxicities":[83],"normal":[85],"tissues":[86],"vs":[87],"cells,":[89,129],"drug":[91],"resistance":[92],"is":[93,174],"generally":[94],"present":[95],"de":[96],"novo":[97],"develops":[99],"with":[100,192],"treatment.":[101],"Over":[102],"last":[104],"decade":[105],"so,":[107],"more":[108],"attention":[109],"focused":[112],"different":[114],"approaches.":[116],"These":[117],"include":[118,211],"monoclonal":[122],"antibodies":[123],"(MAbs)":[124],"specifically":[126],"target":[127],"small":[131],"molecule-inhibitors":[132],"cell-signaling":[134,209],"pathways":[135,210],"that":[136,166,173],"linked":[139],"oncogenesis":[141],"maintenance":[143],"malignant":[146],"phenotype.":[147],"For":[148],"example,":[149],"former":[151],"approach":[152],"seen":[154],"licensing":[158],"Herceptin\u00ae":[160],"(trastuzumab;":[161],"Genentech/Roche),":[162],"a":[163,169],"humanized":[164],"MAb":[165],"targets":[167],"erbB2/HER2,":[168],"receptor":[170],"tyrosine":[171],"kinase":[172],"overexpressed":[175],"some":[177],"30%":[178],"shown":[184],"promising":[185],"activity":[187],"when":[188],"used":[189],"combination":[191],"metastatic":[199],"(,":[202],",":[203],").":[204],"Promising":[205],"small-molecule":[206],"inhibitors":[207],"Gleevec\u2122":[212],"(STI571,":[213],"imitanib":[214],"mesylate;":[215],"Novartis)":[216],"Iressa\u2122":[218],"(ZD1839,":[219],"gefitinib;":[220],"AstraZeneca).":[221]},"counts_by_year":[{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}